AI assistant
PFIZER INC — Director's Dealing 2025
Feb 26, 2025
29831_dirs_2025-02-25_80722ed2-e973-4c00-b3a4-a1ad589b0294.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2025-02-22
Reporting Person: McDermott Michael (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-22 | Common Stock | M | 11125.0000 | $30.1700 | Acquired | 87636.0000 | Direct |
| 2025-02-22 | Common Stock | F | 497.0000 | $26.3000 | Disposed | 87139.0000 | Direct |
| 2025-02-22 | Common Stock | F | 9925.0000 | $26.0800 | Disposed | 77214.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-22 | Stock Appreciation Rights | $30.1700 | M | 11125.0000 | Disposed | 2025-02-22 | Common Stock (11125.0000) | Direct |
Footnotes
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: Price is the closing price of Pfizer common stock on February 21, 2025.
F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.